Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Regeneron Pharmaceuticals has received a consensus rating of "Moderate Buy" from 29 brokerages, with three analysts assigning a strong buy rating and one a sell rating.
• The company reported $12.89 EPS for the latest quarter, significantly exceeding the analysts' consensus estimate of $8.43.
• Regeneron announced a quarterly dividend of $0.88, reflecting a yield of 0.6% and a payout ratio of 8.87%.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty-nine brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $817.8750.

A number of equities analysts have recently weighed in on REGN shares. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the period. Farther Finance Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 9.6% in the first quarter. Farther Finance Advisors LLC now owns 628 shares of the biopharmaceutical company's stock valued at $387,000 after buying an additional 55 shares during the period. GAMMA Investing LLC raised its holdings in Regeneron Pharmaceuticals by 41.8% in the first quarter. GAMMA Investing LLC now owns 1,286 shares of the biopharmaceutical company's stock valued at $816,000 after buying an additional 379 shares during the period. Ritholtz Wealth Management raised its holdings in Regeneron Pharmaceuticals by 7.8% in the first quarter. Ritholtz Wealth Management now owns 486 shares of the biopharmaceutical company's stock valued at $308,000 after buying an additional 35 shares during the period. Finally, Mission Wealth Management LP raised its holdings in Regeneron Pharmaceuticals by 47.7% in the first quarter. Mission Wealth Management LP now owns 786 shares of the biopharmaceutical company's stock valued at $498,000 after buying an additional 254 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 2.7%

Shares of Regeneron Pharmaceuticals stock opened at $572.60 on Wednesday. The company has a market cap of $60.69 billion, a P/E ratio of 14.43, a PEG ratio of 1.78 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,024.36. The firm has a fifty day moving average of $573.72 and a two-hundred day moving average of $563.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 EPS. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.